Company intelligence / Profile preview

Biotec Pharmacon ASA

Ownership: Private
Development stage: Phase 2

Overview

The company had Phase III trials for SBG (Soluble Beta-Glucan) for diabetic foot ulcers that were not positive according to 2009 results. They also conducted early phase (I/II) studies on combining SBG with anti-cancer antibodies in neuroblastoma, and animal studies showing promising effects for inflammatory bowel disease.

Therapeutic areas: GastroenterologyEndocrinologyOncologyDermatology
Modalities: Beta-glucansenzymes
Industry: Biotech

Drug pipeline

1 asset

SBG

Phase 2

Indications: Cancer, Diabetic ulcers, Periodontitis, Mucositis

Beyond the preview

Go deeper on Biotec Pharmacon ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotec Pharmacon ASA.

Explore the full profile